The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis

Angiogenesis

Volumn 13, Issue 3, 2010, Pages 259-267

  Martiny Baron, Georg ^a   Holzer, Philipp ^a   Billy, Eric ^a   Schnell, Christian ^a   Brueggen, Joseph ^a   Ferretti, Mireille ^a   Schmiedeberg, Niko ^a   Wood, Jeanette M ^b   Furet, Pascal ^a   Imbach, Patricia ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b S BIO Pte Ltd   (Singapore)

Author keywords

Angiogenesis; EphB4; EphrinB2; Protein kinase inhibitor; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; EPHRIN B2; EPHRIN RECEPTOR B4; NVP BHG 712; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; CELL ASSAY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG RETENTION; DRUG STRUCTURE; DRUG TISSUE LEVEL; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BIOLOGICAL ASSAY; HUMANS; LUNG; MICE; NEOVASCULARIZATION, PATHOLOGIC; ORGAN SIZE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; RECEPTOR, EPHB4; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78149412006     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-010-9183-z     Document Type: Article

References (46)

1. GD Yancopoulos S Davis NW Gale JS Rudge SJ Wiegand J Holash 2000 Vascular-specific growth factors and blood vessel formation Nature 407 242 248 1:CAS:528:DC%2BD3cXmvVSlsrY%3D 10.1038/35025215 11001067
2. EB Pasquale 2008 Eph-ephrin bidirectional signaling in physiology and disease Cell 133 38 52 1:CAS:528:DC%2BD1cXkslOlu7o%3D 10.1016/j.cell.2008.03.011 18394988 (Pubitemid 351442996)
3. SS Gerety HU Wang ZF Chen DJ Anderson 1999 Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development Mol Cell 4 403 414 1:CAS:528:DyaK1MXmsVChsL8%3D 10.1016/S1097-2765(00)80342-1 10518221 (Pubitemid 29499793)
4. HU Wang ZF Chen DJ Anderson 1998 Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4 Cell 93 741 753 1:CAS:528:DyaK1cXjsl2ktrs%3D 10.1016/S0092-8674(00)81436-1 9630219 (Pubitemid 28257581)
5. SR Kumar J Singh G Xia V Krasnoperov L Hassanieh EJ Ley J Scehnet NG Kumar D Hawes MF Press FA Weaver PS Gill 2006 Receptor tyrosine kinase EphB4 is a survival factor in breast cancer Am J Pathol 169 279 293 1:CAS:528: DC%2BD28XnslSntb0%3D 10.2353/ajpath.2006.050889 16816380
6. SA Stephenson S Slomka EL Douglas PJ Hewett JE Hardingham 2001 Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer BMC Mol Biol 2 15 1:STN:280:DC%2BD3szhslCrtQ%3D%3D 10.1186/1471-2199-2-15 11801186 (Pubitemid 38692999)
7. W Liu SA Ahmad YD Jung N Reinmuth F Fan CD Bucana LM Ellis 2002 Coexpression of ephrin-Bs and their receptors in colon carcinoma Cancer 94 934 939 1:CAS:528:DC%2BD38XitVKhs7w%3D 10.1002/cncr.10122 11920461 (Pubitemid 34150847)
8. G Berclaz E Karamitopoulou L Mazzucchelli V Rohrbach E Dreher A Ziemiecki AC Andres 2003 Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma Ann Oncol 14 220 226 1:STN:280:DC%2BD3s%2Flt12kuw%3D%3D 10.1093/annonc/mdg072 12562648 (Pubitemid 36305433)
9. YC Lee JR Perren EL Douglas MP Raynor MA Bartley PG Bardy SA Stephenson 2005 Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma BMC Cancer 5 119 10.1186/1471-2407-5-119 16171530 (Pubitemid 41461016)
10. G Castellano JF Reid P Alberti ML Carcangiu A Tomassetti S Canevari 2006 New potential ligand-receptor signaling loops in ovarian cancer identified in multiple gene expression studies Cancer Res 66 10709 10719 1:CAS:528: DC%2BD2sXivVyqsL4%3D 10.1158/0008-5472.CAN-06-1327 17090524 (Pubitemid 44876966)
11. NK Noren M Lu AL Freeman M Koolpe EB Pasquale 2004 Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth Proc Natl Acad Sci U S A 101 5583 5588 1:CAS:528:DC%2BD2cXjsVagu7g%3D 10.1073/pnas. 0401381101 15067119 (Pubitemid 38481199)
12. E Batlle J Bacani H Begthel S Jonkheer A Gregorieff M van de Born N Malats E Sancho E Boon T Pawson S Gallinger S Pals H Clevers 2005 EphB receptor activity suppresses colorectal cancer progression Nature 435 1126 1130 1:CAS:528:DC%2BD2MXltl2ntr4%3D 10.1038/nature03626 15973414 (Pubitemid 40910522)
13. NK Noren G Foos CA Hauser EB Pasquale 2006 The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway Nat Cell Biol 8 815 825 1:CAS:528:DC%2BD28XnsFWqtbY%3D 10.1038/ncb1438 16862147 (Pubitemid 44151584)
14. H Dopeso S Mateo-Lozano R Mazzolini P Rodrigues L Lagares-Tena J Ceron J Romero M Esteves S Landolfi J Hernandez-Losa J Castano AJ Wilson S Ramon y Cajal JM Mariadason S Schwartz Jr D Arango 2009 The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis Cancer Res 69 7430 7438 1:CAS:528:DC%2BD1MXhtFaku7vK 10.1158/0008-5472.CAN-09-0706 19738063
15. G Xia SR Kumar R Masood S Zhu R Reddy V Krasnoperov DI Quinn SM Henshall RL Sutherland JK Pinski S Daneshmand M Buscarini JP Stein C Zhong D Broek P Roy-Burman PS Gill 2005 EphB4 expression and biological significance in prostate cancer Cancer Res 65 4623 4632 1:CAS:528:DC%2BD2MXks1OhtLg%3D 10.1158/0008-5472.CAN-04-2667 15930280 (Pubitemid 40740798)
16. NK Noren EB Pasquale 2007 Paradoxes of the EphB4 receptor in cancer Cancer Res 67 3994 3997 1:CAS:528:DC%2BD2sXltVykurk%3D 10.1158/0008-5472.CAN-07- 0525 17483308 (Pubitemid 46815041)
17. G Martiny-Baron T Korff F Schaffner N Esser S Eggstein D Marme HG Augustin 2004 Inhibition of tumor growth and angiogenesis by soluble EphB4 Neoplasia 6 248 257 1:CAS:528:DC%2BD2cXlt1equrs%3D 10.1593/neo.03457 15153337
18. S He Y Ding J Zhou V Krasnoperov S Zozulya SR Kumar SJ Ryan PS Gill DR Hinton 2005 Soluble EphB4 regulates choroidal endothelial cell function and inhibits laser-induced choroidal neovascularization Invest Ophthalmol Vis Sci 46 4772 4779 10.1167/iovs.05-0502 16303978 (Pubitemid 44264583)
19. M Koolpe R Burgess M Dail EB Pasquale 2005 EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity J Biol Chem 280 17301 17311 1:CAS:528:DC%2BD2MXjsFOgurs%3D 10.1074/jbc.M500363200 15722342 (Pubitemid 41389199)
20. JE Chrencik A Brooun MI Recht ML Kraus M Koolpe AR Kolatkar RH Bruce G Martiny-Baron H Widmer EB Pasquale P Kuhn 2006 Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity Structure 14 321 330 1:CAS:528: DC%2BD28XhtlKltrg%3D 10.1016/j.str.2005.11.011 16472751 (Pubitemid 43202021)
21. Krasnoperov V, Kumar SR, Ley E, Li X, Scehnet J, Liu R, Zozulya S, Gill PS (2010) Novel EphB4 Monoclonal Antibodies Modulate Angiogenesis and Inhibit Tumor Growth. Am J Pathol
22. RH Adams F Diella S Hennig F Helmbacher U Deutsch R Klein 2001 The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration Cell 104 57 69 1:CAS:528: DC%2BD3MXis1OqsrY%3D 10.1016/S0092-8674(01)00191-X 11163240 (Pubitemid 32144972)
23. AC Andres N Munarini V Djonov S Bruneau G Zuercher S Loercher V Rohrbach A Ziemiecki 2003 EphB4 receptor tyrosine kinase transgenic mice develop glomerulopathies reminiscent of aglomerular vascular shunts Mech Dev 120 511 516 1:CAS:528:DC%2BD3sXisV2lu78%3D 10.1016/S0925-4773(02)00461-6 12676328 (Pubitemid 36379266)
24. N Kertesz V Krasnoperov R Reddy L Leshanski SR Kumar S Zozulya PS Gill 2006 The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth Blood 107 2330 2338 1:CAS:528:DC%2BD28XisFOjtLY%3D 10.1182/blood-2005-04-1655 16322467 (Pubitemid 43345552)
25. C Bardelle T Coleman D Cross S Davenport JG Kettle EJ Ko AG Leach A Mortlock J Read NJ Roberts P Robins EJ Williams 2008 Inhibitors of the tyrosine kinase EphB4. Part 2: structure-based discovery and optimisation of 3, 5-bis substituted anilinopyrimidines Bioorg Med Chem Lett 18 5717 5721 1:CAS:528:DC%2BD1cXht12rsrbF 10.1016/j.bmcl.2008.09.087 18851911
26. C Bardelle D Cross S Davenport JG Kettle EJ Ko AG Leach A Mortlock J Read NJ Roberts P Robins EJ Williams 2008 Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2, 4-bis-anilinopyrimidines Bioorg Med Chem Lett 18 2776 2780 1:CAS:528: DC%2BD1cXlvVWjsr4%3D 10.1016/j.bmcl.2008.04.015 18434142 (Pubitemid 351622047)
27. SA Mitchell MD Danca PA Blomgren JW Darrow KS Currie JE Kropf SH Lee SL Gallion JM Xiong DA Pippin RW DeSimone DR Brittelli DC Eustice A Bourret M Hill-Drzewi PM Maciejewski LL Elkin 2009 Imidazo[1, 2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4 Bioorg Med Chem Lett 19 6991 6995 1:CAS:528:DC%2BD1MXhsVWht7bO 10.1016/j.bmcl.2009.10.037 19879134
28. K Lafleur D Huang T Zhou A Caflisch C Nevado 2009 Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4) J Med Chem 52 6433 6446 1:CAS:528:DC%2BD1MXhtF2qtLzP 10.1021/jm9009444 19788238
29. JM Wood G Bold E Buchdunger R Cozens S Ferrari J Frei F Hofmann J Mestan H Mett T O'Reilly E Persohn J Rosel C Schnell D Stover A Theuer H Towbin F Wenger K Woods-Cook A Menrad G Siemeister M Schirner KH Thierauch MR Schneider J Drevs G Martiny-Baron F Totzke 2000 PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration Cancer Res 60 2178 2189 1:CAS:528:DC%2BD3cXivVaksb0%3D 10786682
30. Holzer P, Imbach P, Furet P, Schmiedeberg N (2007) 3-(Substituted Amino)-Pyrazolo[3,4-d]Pyrimidines as EphB and VEGFR2 Kinase Inhibitors. In: W.I.P. Organization (ed) WO 2007/062805 A1
31. C Garcia-Echeverria MA Pearson A Marti T Meyer J Mestan J Zimmermann J Gao J Brueggen HG Capraro R Cozens DB Evans D Fabbro P Furet DG Porta J Liebetanz G Martiny-Baron S Ruetz F Hofmann 2004 In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase Cancer Cell 5 231 239 1:CAS:528:DC%2BD2cXjtVartbk%3D 10.1016/S1535-6108(04)00051-0 15050915 (Pubitemid 38402115)
32. PW Manley P Drueckes G Fendrich P Furet J Liebetanz G Martiny-Baron J Mestan J Trappe M Wartmann D Fabbro 2009 Extended kinase profile and properties of the protein kinase inhibitor nilotinib Biochim Biophys Acta 1804 445 453 19922818
33. G Mathis 1995 Probing molecular interactions with homogeneous techniques based on rare earth cryptates and fluorescence energy transfer Clin Chem 41 1391 1397 1:CAS:528:DyaK2MXotV2ns7Y%3D 7656455
34. CC Weber H Cai M Ehrbar H Kubota G Martiny-Baron W Weber V Djonov E Weber AS Mallik M Fussenegger K Frei JA Hubbell AH Zisch 2005 Effects of protein and gene transfer of the angiopoietin-1 fibrinogen-like receptor-binding domain on endothelial and vessel organization J Biol Chem 280 22445 22453 1:CAS:528:DC%2BD2MXksl2htLk%3D 10.1074/jbc.M410367200 15781448 (Pubitemid 40827900)
35. HA Lane JM Wood PM McSheehy PR Allegrini A Boulay J Brueggen A Littlewood-Evans SM Maira G Martiny-Baron CR Schnell P Sini T O'Reilly 2009 mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor Clin Cancer Res 15 1612 1622 1:CAS:528:DC%2BD1MXisVWrsr0%3D 10.1158/1078-0432.CCR-08-2057 19223496
36. RH Adams R Klein 2000 Eph receptors and ephrin ligands. Essential mediators of vascular development Trends Cardiovasc Med 10 183 188 1:CAS:528:DC%2BD3MXitF2ktrc%3D 10.1016/S1050-1738(00)00046-3 11282292 (Pubitemid 32229885)
37. SS Gerety DJ Anderson 2002 Cardiovascular ephrinB2 function is essential for embryonic angiogenesis Development 129 1397 1410 1:CAS:528: DC%2BD38XivFShsr4%3D 11880349
38. RH Adams GA Wilkinson C Weiss F Diella NW Gale U Deutsch W Risau R Klein 1999 Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis Genes Dev 13 295 306 1:CAS:528:DyaK1MXht1KgtbY%3D 10.1101/gad.13.3.295 9990854
39. N Cheng DM Brantley J Chen 2002 The ephrins and Eph receptors in angiogenesis Cytokine Growth Factor Rev 13 75 85 1:CAS:528:DC%2BD3MXpt1ahurg%3D 10.1016/S1359-6101(01)00031-4 11750881 (Pubitemid 34436963)
40. T Kojima TY Chung JH Chang R Sayegh FH Casanova DT Azar 2007 Comparison of EphA receptor tyrosine kinases and ephrinA ligand expression to EphB-ephrinB in vascularized corneas Cornea 26 569 578 17525654
41. J Chen D Hicks D Brantley-Sieders N Cheng GW McCollum X Qi-Werdich J Penn 2006 Inhibition of retinal neovascularization by soluble EphA2 receptor Exp Eye Res 82 664 673 1:CAS:528:DC%2BD28Xos1ahug%3D%3D 10.1016/j.exer.2005.09.004 16359662 (Pubitemid 43122097)
42. DM Brantley-Sieders WB Fang DJ Hicks G Zhuang Y Shyr J Chen 2005 Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression Faseb J 19 1884 1886 1:CAS:528:DC%2BD2MXht1emtrrJ 16166198
43. T Okazaki A Ni P Baluk OA Ayeni J Kearley AJ Coyle A Humbles DM McDonald 2009 Capillary defects and exaggerated inflammatory response in the airways of EphA2-deficient mice Am J Pathol 174 2388 2399 1:CAS:528:DC%2BD1MXmvFyjsLY%3D 10.2353/ajpath.2009.080949 19443703
44. I Kim YS Ryu HJ Kwak SY Ahn JL Oh GD Yancopoulos NW Gale GY Koh 2002 EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells Faseb J 16 1126 1128 1:CAS:528:DC%2BD38XltlChu7w%3D 12039842
45. S Sawamiphak S Seidel CL Essmann GA Wilkinson ME Pitulescu T Acker A Acker-Palmer 2010 Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis Nature 465 487 491 1:CAS:528:DC%2BC3cXls12qurw%3D 10.1038/nature08995 20445540
46. Y Wang M Nakayama ME Pitulescu TS Schmidt ML Bochenek A Sakakibara S Adams A Davy U Deutsch U Luthi A Barberis LE Benjamin T Makinen CD Nobes RH Adams 2010 Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis Nature 465 483 486 1:CAS:528:DC%2BC3cXls12qur4%3D 10.1038/nature09002 20445537